We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Johnson and Johnson (J&J) have noted the lack of evidence that its HIV drug darunavir has antiviral activity against SARS-CoV-2, the novel coronavirus that causes Covid-19.
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.